KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBT Margin (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of EBT Margin data on record, last reported at 29.58% in Q4 2025.

  • For Q4 2025, EBT Margin fell 796.0% year-over-year to 29.58%; the TTM value through Dec 2025 reached 2.48%, down 478.0%, while the annual FY2025 figure was 2.48%, 478.0% down from the prior year.
  • EBT Margin reached 29.58% in Q4 2025 per CRL's latest filing, down from 8.68% in the prior quarter.
  • Across five years, EBT Margin topped out at 22.27% in Q4 2022 and bottomed at 29.58% in Q4 2025.
  • Average EBT Margin over 5 years is 8.52%, with a median of 11.89% recorded in 2022.
  • Peak YoY movement for EBT Margin: skyrocketed 419bps in 2022, then crashed -4222bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 18.08% in 2021, then grew by 23bps to 22.27% in 2022, then decreased by -8bps to 20.59% in 2023, then tumbled by -205bps to 21.62% in 2024, then plummeted by -37bps to 29.58% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 29.58% in Q4 2025, 8.68% in Q3 2025, and 6.92% in Q2 2025.